Neogenomics Shares Poised for Breakthrough with New Cancer Test Data

Strong Quarterly Performance Sets Stage

Neogenomics finds itself at a potential inflection point this weekend as the company prepares to unveil groundbreaking clinical data for its RaDaR ST liquid biopsy assay at an international conference. This presentation comes on the heels of the stock’s 1.19% advance to $9.81 in Thursday’s session, leaving investors wondering whether more substantial gains lie ahead.

The timing of these developments builds upon recently reported quarterly results that exceeded market expectations. Neogenomics demonstrated robust operational performance with:
* Revenue growth of 11.9% to $187.8 million
* Clinical test volumes expanding by 15%
* Next-generation sequencing and minimal residual disease testing emerging as key growth drivers for 2026